Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof

A technology of solvates and compounds, applied in the field of medicine, to achieve the effects of high yield, more absorption, and long half-life

Active Publication Date: 2012-10-31
BEIJING PRELUDE PHARM SCI & TECH
View PDF6 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Therefore, one object of the present invention is to provide a kind of novel compound or pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture thereof of sodium-dependent glucose transporter (SGLT2) inhibitory activity , to address the deficiencies of existing antidiabetic and related disease treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
  • Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
  • Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121] Embodiment 1: the preparation of compound 2 of the present invention

[0122]

[0123] step 1):

[0124]

[0125] At -7°C, (3R, 4S, 5S, 6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-one (14.2g) and N - To a solution of methylmorpholine (80 mL) in dry THF (120 mL) was added TMSCl (71 mL), then the mixture was slowly warmed to room temperature and stirred overnight. At 10 ° C, toluene (160 mL) and H 2 O (300 mL) was poured into the mixture, then washed with H 2 The organic phase was washed with O (120 mL), 1M HCl (150 mL x 4) and brine (120 mL). Na 2 SO 4 It was dried and then concentrated to give crude product which was purified by silica gel column chromatography (PE / EA=10 / 1). 30 g of (3R,4S,5R,6R)-3,4,5-tris(trimethylsilyloxy)-6-((trimethylsilyloxy)methyl)tetrahydro-2H-pyran were obtained -2-one.

[0126] Step (2):

[0127]

[0128] To a solution of 5-bromo-2-chlorobenzoic acid (40 g) in DCM (300 mL) was added dropwise (COCl) at room t...

Embodiment 2

[0153] Embodiment 2: the preparation of compound 3 of the present invention

[0154]

[0155] step 1):

[0156]

[0157] With embodiment 1 step (1).

[0158] Step (2):

[0159]

[0160] With embodiment 1 step (2).

[0161] Step (3):

[0162]

[0163] With embodiment 1 step (3).

[0164] Step (4)-1:

[0165]

[0166] To a solution of (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone in dry DCM was slowly added BBr at -78 °C 3 (4.4g, 3eq), then the mixture was stirred at 0°C for 1 h and 24g at room temperature. TLC (PE / EA=1 / 1) showed the starting material was completely reacted. Slowly add saturated NaHCO to the mixture 3 , to adjust the pH to 8-9. The mixture was then extracted with DCM, the combined organic phases were washed with Na 2 SO 4 Dry and concentrate. The crude product (2.5 g) was used directly in the next step.

[0167] Step (4)-2:

[0168]

[0169] To a solution of (5-bromo-2-chlorophenyl)(4-hydroxyphenyl)methanone (6.2 g) in dry DMF...

Embodiment 3

[0184] Embodiment 3: in vitro stability test

[0185] In this example, the in vitro metabolic stability of compound 2 and compound 3 of the present invention was tested, and compared with known compound 1.

[0186] Test compounds: compound 1, compound 2 and compound 3;

[0187] Control compound: verapamil.

[0188] Microsomes: Human liver microsomes (HMMC; PL050B) and male rat liver microsomes (RTMC; RT046) were purchased from CellzDirect (Invitrogen); stored at -80°C until use.

[0189] method:

[0190] 1) Prepare the mother solution as shown in Table 1, and then add the test compound or control compound, so that the final concentration of these compounds in the reaction system is 2 μM. The mixed solution was then preheated at 37°C for 2 minutes.

[0191] Table 1. Preparation of mother liquors

[0192]

[0193] 2) NADPH was added to the mixed solution to make the final concentration 1 mM, and then the reaction system was placed at 37°C. In the blank control, the sa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A compound represented by formula I, or a pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture thereof, wherein, R1 and R2 are independently hydrogen, -OH, alkyl, -CF3, -OCHF2, -OCF3 or halogen,R3 is cycloalkyl, -OCH2CF3, -OCH2CHF2, -OCH2CH2F or -OCH2CH3,R4 is hydrogen, -OH, -O aryl, -OCH2 aryl, alkyl, cycloalkyl, -CF3, -OCHF2, -OCF3, -OCH2CF3, -OCH2CHF2, -OCH2CH2F or halogen,A is -CX1X2, wherein X1 and X2 are independently H, F and Cl, and when both X1 and X2 are H, R3 is other than -OCH2CH3. The compound has an activity of inhibitors of sodium-dependent glucose transport protein. A method for preparing the compound. A pharmaceutical composition comprising the compound. A use of the compound and pharmaceutical composition thereof in the preparation of medicaments of SGLT2 inhibitors for treating a disease of interest.

Description

technical field [0001] The invention belongs to the field of medicine, in particular, the invention relates to a novel compound having sodium-dependent glucose transporter (SGLT2) inhibitor activity, a preparation method of the compound, a pharmaceutical composition comprising the compound, and the compound And the application of the pharmaceutical composition in the preparation of SGLT2 inhibitor drugs. Background technique [0002] Research data show that the number of diabetic patients worldwide has increased from 150 million in 2000 to 280 million, and it is estimated that nearly 500 million people worldwide will suffer from diabetes by 2030. Diabetes can lead to infection, heart disease, cerebrovascular disease, renal failure, blindness, gangrene of lower extremities, etc., which will have a huge impact and harm on patients' physical and mental health and normal life. [0003] Pathologically, diabetes is a series of clinical syndromes caused by absolute or relative ins...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D309/10A61K31/351A61P3/04A61P3/06A61P3/10A61P5/48A61P9/10A61P9/12
CPCC07H7/04A61K9/1652A61K9/2059A61K9/2018A61K31/351C07D309/10A61K45/06A61K9/1635A61K9/2027A61K31/70A61K9/1623A61K9/0019A61P13/12A61P25/00A61P27/02A61P3/04A61P3/06A61P5/48A61P9/00A61P9/10A61P9/12A61P3/10A61K2300/00
Inventor 王志岩
Owner BEIJING PRELUDE PHARM SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com